Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Bonothyrk iconBonothyrkSmall moleculeNo amino acid sequence. Icon reflects category theme only.

Bonothyrk

Beginner tier: 10 mg, daily · 4w on / 16w off · community consensus

MetabolicResearch
~2-6 hours half-life (estimated)·Oral

Also known as: A-21, Peptide Complex A-21, Parathyroid Peptide Bioregulator

Four amino acids from a calf parathyroid gland, swallowed as a capsule for 30 days, then nothing for months. Bonothyrk (Peptide Complex A-21) is a Khavinson bioregulator targeting parathyroid chief cells through epigenetic gene expression changes. The only clinical observation comes from 33 perimenopausal women at the St. Petersburg Institute of Bioregulation and Gerontology, where 40 mg/day for 30 days improved bone mineral density markers versus controls. That study has no PMID, no journal publication, and no independent replication. Users in European longevity circles report reduced muscle cramping within two weeks. Bone outcomes require DEXA verification.

What Is Bonothyrk?

Thirty-three women and zero PubMed results. That's the full clinical evidence base for Bonothyrk, a bovine-derived parathyroid peptide bioregulator also known as Peptide Complex A-21.

Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology developed this product. It contains short-chain polypeptides (2 to 7 amino acid residues) extracted from the parathyroid glands of young cattle. The proposed mechanism: peptide fragments cross cell membranes, enter parathyroid chief cell nuclei, and bind DNA promoter regions. This theoretically modulates gene expression controlling parathyroid hormone (PTH) synthesis and calcium-sensing receptor (CaSR) sensitivity.

Users take 10 mg capsules orally for 30-day courses, repeated two to three times per year. The carry-forward effect draws the most interest; gene expression changes are thought to persist three to six months after stopping. Community experience on Longecity (thread 111763) and product review sections tracks fewer than 50 identifiable reports. Reduced muscle cramp frequency is the most consistent subjective outcome.

The sole clinical observation tracked 33 perimenopausal women (ages 47 to 56) receiving 40 mg/day for 30 days. BMD parameters improved compared to controls. This study was never published in a peer-reviewed journal and carries no PMID. Broader Khavinson bioregulator research has indexed support [1][2], but those papers don't validate parathyroid-specific claims. Khavinson died in 2024, ending primary institutional output. Objective benefit assessment requires DEXA scanning and lab monitoring.

How Bonothyrk Works

The proposed mechanism sits entirely within Khavinson's bioregulatory framework. Short-chain peptide fragments (2 to 7 amino acid residues) derived from bovine parathyroid tissue absorb orally and theoretically reach parathyroid chief cells via intestinal peptide transporters.

Once inside the cell, these fragments cross the nuclear membrane and bind to complementary sequences in gene promoter regions. This modulates RNA polymerase activity, triggering transcription of proteins involved in PTH synthesis and secretion. At the epigenetic level, the peptides may alter DNA methylation patterns. The proposed result is a shift toward younger, more functional gene expression in parathyroid tissue.

The downstream target is the calcium-sensing receptor (CaSR). CaSR sensitivity declines with age, meaning parathyroid cells respond less accurately to blood calcium fluctuations. Restored CaSR function would mean better-regulated PTH release. PTH governs three calcium pathways simultaneously: renal reabsorption, skeletal mobilization, and intestinal absorption through vitamin D activation.

None of this has been confirmed specifically for Bonothyrk. The mechanism is extrapolated from general Khavinson peptide research on peptide-DNA interactions [3][4]. No Western lab has independently verified parathyroid-specific epigenetic effects from oral administration of this complex.

Bonothyrk Benefits

  • Bonothyrk benefits center on parathyroid function and calcium metabolism, though evidence remains limited to one unindexed clinical observation and fewer than 50 community reports.
  • Bone mineral density improvement: 33 perimenopausal women (ages 47 to 56) showed improved BMD parameters after 40 mg/day for 30 days versus controls (Khavinson, unpublished institute data).
  • Muscle cramp reduction is the most consistently reported subjective benefit across Longecity forum posts (thread 111763) and product reviews; users attribute this to restored calcium signaling.
  • Carry-forward effects lasting three to six months post-course. You run 30 days on and then stop for months without daily maintenance dosing.
  • Oral capsule format. No injections, no reconstitution, no refrigeration required.
  • Supports calcium-phosphorus homeostasis through PTH regulation, potentially reducing pathological calcium deposition in blood vessels, muscles, and joints.

Bonothyrk: Science vs Community Consensus

Aligned
Scientific Evidence
Weak
Based on 6 key studies·Research only

No PubMed-indexed studies exist specifically on Bonothyrk.

Dosing studied: 20–40 mg/day oral (2–4 capsules)
Read the evidence (key study, limitations)

The sole cited clinical observation (33 perimenopausal women, 40 mg/day × 30 days, measurable BMD improvement) is unpublished Russian institute data circulated as marketing copy. It has no PMID, journal, or independent verification. Broader Khavinson class studies [1][2] support the general bioregulation framework but do not validate parathyroid-specific effects. No independent Western replication exists. Khavinson died 2024, ending primary institutional output.

Key Study

Khavinson et al. (unpublished/unindexed): 33 perimenopausal women aged 47–56, 40 mg/day × 30 days: improved BMD parameters vs. controls. No PMID. Broader class reference: PMID 23734519 (Peptide bioregulators geroprotectors Communication 1, 2013).

Limitations

Zero independent replication; all evidence originates from the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson group); primary clinical study is not peer-reviewed in any indexed journal; no English-language RCT; no PK data specific to this compound; mechanism remains theoretical.

Community Experience
Weak
3.5/5
Based on very small: fewer than 50 identifiable community reports

Minimal community presence.

Community dosing: 10–40 mg/day oral (1–4 capsules/day)
Read the reports (what users report 3, common issues 4)

Usage concentrated in European and Russian longevity/biohacker circles via Longecity forum and product review sections. Zero Reddit threads indexed. Most users cannot verify bone outcomes without DEXA. Carry-forward effect (3–6 months post-course) is the most cited practical advantage.

What users report (3)
  • Reduced muscle cramps and spasms (most consistently reported subjective benefit; attributed to restored calcium signaling)
  • Bone density support (primary purchase driver; requires DEXA to verify)
  • Persistent carry-forward effect lasting 3–6 months post-course (valued for low-frequency dosing structure: no continuous daily use required)
Common issues (4)
  • No short-term subjective feedback: epigenetic mechanism means outcomes are slow and require labs to verify
  • High cost relative to evidence base (~$130–$145/60 caps with no English-indexed RCT)
  • Supply inconsistency: frequently out of stock; importing from Russia/Europe adds delay and customs risk
  • Requires full 30-day course: early discontinuation is the most cited cause of perceived inefficacy
Science & Community Aligned

Community-reported benefits (muscle cramp reduction, bone support) align with the theoretical Khavinson parathyroid mechanism. Neither side contradicts the other. However, both evidence streams are weak: science is limited to one unpublished institute observation; community volume is too low for reliable sentiment analysis. Alignment reflects absence of contradiction, not corroboration by independent data.

Bonothyrk Dosage Guide

CommunityKhavinson Institute protocol
LevelDoseFrequency
Beginner10 mgDaily
Moderate10 mg2x Daily
Aggressive20 mg2x Daily
Note:

Each capsule contains 10 mg of the parathyroid peptide complex (A-21). No reconstitution, no syringes, no bacteriostatic water. Oral capsule.

The 20-cap box provides one 10-day conservative course at 20 mg/day (2 capsules). The 60-cap box covers a full 30-day course at that same dose. Running the aggressive 40 mg/day protocol burns 4 capsules daily; you'll need two 60-cap boxes for one course.

Take capsules with food. Fasted dosing is the main cause of GI complaints. Morning and midday with meals; skip the evening dose.

You won't feel this working. The mechanism is epigenetic gene expression modulation in parathyroid cells. There's no acute signal, no mood change, no energy shift. Muscle cramp reduction around week 2 is the earliest subjective marker. Bone outcomes require DEXA imaging at 6 months. Don't bump the dose because nothing "happened" by day 10.

Check serum calcium before starting. If it's above 10.2 mg/dL, don't start. Authentic product carries NPCRIZ labeling and comes in sealed blister packs. Chain of custody can't be verified for marketplace listings.

Cycling Protocol

On Period
4 weeks
Off Period
16 weeks

Standard Khavinson protocol: 30-day course of daily oral capsules, repeated 2-3 times per year with 4-6 month intervals between courses. Some practitioners recommend an initial loading phase of two courses with a 1-month break in between for individuals with significant parathyroid or calcium metabolism concerns.

Calculate your Bonothyrk dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Bonothyrk Protocols by Goal

beginnerCommunity10 days on, ~80 days off (quarterly cadence)
10-day maintenance course
Wk 1.5
20 mg/day (2 × 10 mg capsules, taken together once daily with a meal) · Once daily · Oral

Expected: Parathyroid gland support and calcium metabolism normalization; muscle cramp reduction is the most detectable subjective marker. Objective outcomes require DEXA scan at 6-month mark.

Monitor: Check serum calcium (total + ionized) before starting first course. Recheck at course end. Monitor intact PTH and serum phosphorus at 6-month interval.

How to Use Bonothyrk

  1. 1
    Step 1

    Get baseline labs before your first course: serum calcium (total and ionized), intact PTH, serum phosphorus. Rule out pre-existing hypercalcemia.

  2. 2
    Select your dose level

    Beginner: 1 capsule (10 mg) once daily. Standard: 2 capsules (20 mg) once daily with breakfast. Aggressive: 2 capsules (20 mg) twice daily, morning and midday, each with a meal (40 mg/day total).

  3. 3
    Swallow capsules whole with water

    Don't crush or open them. Always take with food.

  4. 4
    Time doses for morning and early afternoon

    Avoid evening dosing.

  5. 5
    Continue for 30 consecutive days

    Don't skip days. Don't extend past 30 days at the aggressive dose.

  6. 6
    After day 30, recheck serum calcium and intact PTH

    Compare to baseline.

  7. 7
    Stop dosing

    Wait four to six months before the next course. The carry-forward effect sustains gene expression changes during this gap.

  8. 8
    Repeat two to three times per year

    Get a DEXA scan at baseline and at six months.

  9. 9
    Step 9

    Sublingual version: 5 to 6 drops held under the tongue for 10 to 15 minutes, 3 to 4 times daily. Total daily dose is 7.5 to 14 mg (lower than oral capsules). No bioavailability comparison study exists.

  10. 10
    Step 10

    Store in original blister packaging at 15 to 25 degrees Celsius, away from moisture and light.

Alternative Routes

Sublingual (lingual drops)

5–6 drops (~2.5–3.5 mg/dose) held sublingually for 10–15 minutes, 3–4×/day = ~7.5–14 mg total daily dose: substantially lower than oral capsule protocol (20–40 mg/day)

Bypasses first-pass hepatic metabolism and gut acid degradation, theoretically improving bioavailability per unit dose. However, total daily peptide exposure is lower than the capsule protocol. Practical advantage for users with GI sensitivity or swallowing difficulty. No head-to-head bioavailability study exists.

Bonothyrk Stacking Protocols

Works With

Avoid

High-dose calcium supplements (>1,000 mg/day elemental calcium)

Additive effect on serum calcium: Bonothyrk stimulates PTH-mediated calcium mobilization; concurrent high-dose calcium supplementation may push serum calcium above reference range

Vitamin D at supraphysiologic doses (>4,000 IU/day)

High-dose vitamin D independently raises serum calcium via intestinal absorption; combined with parathyroid stimulation, hypercalcemia risk increases meaningfully

Thiazide diuretics (hydrochlorothiazide, chlorthalidone)

Thiazides reduce urinary calcium excretion, raising serum calcium independently; additive effect with parathyroid stimulation creates hypercalcemia risk

Lithium (lithium carbonate)

Lithium directly stimulates PTH secretion and causes secondary hyperparathyroidism as a known adverse effect; concurrent use with a parathyroid bioregulator creates unpredictable PTH/calcium dysregulation

Do not combine

Estimated Cost

Brand Price
NPCRIZ / Khavinson Institute (originating Russian manufacturer): ~$156 USD/60 caps (typical import price)
Generic / Research
Licensed versions: ~$55 USD/20-cap pack (10-day course) | $129–$145 USD/60-cap pack (~€114.90 in the EU)

Pricing updated 2026-04-09

Bonothyrk Side Effects

The biggest safety concern with Bonothyrk is not a specific adverse event. It's the near-total absence of controlled safety data. No English-language peer-reviewed study has evaluated this product's safety profile. Everything below comes from Russian clinical observations and a community sample of fewer than 50 identifiable user reports.

Bovine origin introduces a theoretical prion contamination risk. Bonothyrk is derived from the parathyroid glands of young cattle. Any bovine glandular product carries this consideration. No cases of prion disease have been linked to Bonothyrk use. The risk is theoretical but not zero, and it cannot be formally quantified without epidemiological surveillance that doesn't exist for this product. Individuals with formal prion risk factors should consult a physician.

Hypercalcemia is the most clinically actionable risk. Bonothyrk stimulates parathyroid function and PTH-mediated calcium mobilization. Serum calcium can rise above the reference range (above 10.2 mg/dL total). Symptoms: fatigue, nausea, excessive urination, constipation. In severe cases, cardiac arrhythmia. This risk compounds with concurrent calcium supplements above 1,000 mg/day, vitamin D above 4,000 IU/day, thiazide diuretics, or lithium. If serum calcium rises above the normal range (upper limit approximately 10.2 mg/dL), stop dosing and retest in one week.

Lithium users face a specific danger. Lithium directly stimulates PTH secretion and causes secondary hyperparathyroidism as a known adverse effect. Adding a parathyroid bioregulator creates unpredictable PTH and calcium dysregulation. This combination should be avoided.

Gastrointestinal discomfort is the most commonly reported side effect. Nausea and stomach upset occur mainly when capsules are taken without food. At 40 mg/day, split across morning and midday meals. Symptoms typically resolve by day 3 to 5.

Allergic reactions are possible given the bovine protein content. Headache and mild dizziness have been reported occasionally but without frequency data.

For kidney stone formers, PTH stimulation increases urinary calcium excretion. A baseline 24-hour urine calcium test is recommended. If urinary calcium exceeds 300 mg/24h (men) or 250 mg/24h (women), the risk-benefit calculation changes.

Pregnancy and breastfeeding are hard contraindications. No safety data exists. Children under 14 should not use this product. Post-surgical parathyroid removal is a hard contraindication; there is no tissue for Bonothyrk to act on. Individuals with primary hyperparathyroidism or severe renal impairment affecting calcium excretion should not use Bonothyrk.

Check serum calcium before your first course. That single lab draw is the most important safety step.

Common Issues & Solutions

No subjective effects by day 14: Expected: mechanism is epigenetic gene expression modulation in parathyroid cells, not acute pharmacological signaling. Do not increase dose. Complete the full 30-day course; outcomes require lab verification (serum calcium, intact PTH) or DEXA scan.

GI discomfort (nausea, stomach upset): Take capsules with a meal, never fasted. At 40 mg/day, split across morning and midday meals rather than taking all at once. GI symptoms typically resolve by day 3–5.

Elevated serum calcium mid-course: Pause protocol immediately. Retest serum calcium in 1 week. If persistently elevated (>10.5 mg/dL), discontinue and consult an endocrinologist. Reduce or pause concurrent calcium supplementation and high-dose vitamin D.

No measurable benefit after completing first course: Carry-forward effects continue 3–6 months post-course. DEXA scan at baseline and 6 months is required to objectively assess BMD change: bone outcomes cannot be self-assessed without imaging. Muscle cramp frequency reduction is the most accessible subjective marker.

Concerned about bovine origin / prion risk: No cases of prion disease have been reported with Bonothyrk use. Theoretical prion risk is not zero for any bovine-derived glandular product but has not been observed clinically. Individuals with formal prion risk factors should consult a physician before use.

Ask AI about this page

Ask AI for a second opinion on Bonothyrk dosing and side effects

Contraindications

  • Pregnancy and breastfeeding (no safety data available)
  • Known hypersensitivity to bovine-derived glandular products
  • Hypercalcemia or conditions causing elevated blood calcium
  • Primary hyperparathyroidism (overactive parathyroid glands)
  • Children under 14 years of age
  • Severe renal impairment affecting calcium excretion

Drug Interactions

  • Use caution with calcium supplements: additive effects on blood calcium levels possible
  • May interact with vitamin D supplementation by altering calcium absorption dynamics
  • Bisphosphonates and other osteoporosis medications: theoretical interaction through overlapping calcium pathways
  • Thiazide diuretics can raise calcium levels and may compound effects
  • Lithium can affect parathyroid function and may interact unpredictably
  • No formal drug interaction studies have been published for Bonothyrk specifically

Product Quality

Recommended Monitoring

TestWhenTarget
Serum calcium (total and ionized)Before starting first course (baseline); at day 30 (course end); every 6 months during ongoing cyclingTotal calcium: 8.5–10.2 mg/dL | Ionized calcium: 4.6–5.3 mg/dL
Intact PTH (parathyroid hormone)Before starting first course; at day 30 (course end); at 6 months (mid-off period)10–65 pg/mL (intact PTH); interpretation requires clinical context and baseline comparison
Serum phosphorusWith each calcium/PTH panel2.5–4.5 mg/dL
DEXA scan (bone mineral density)Baseline before first course; repeat at 6 months (after 1–2 complete courses)Not listed
24-hour urine calciumBefore starting, for any user with a personal or family history of kidney stones<300 mg/24h (men) | <250 mg/24h (women)
Serum calcium (total and ionized)

Primary safety biomarker: Bonothyrk stimulates parathyroid function. Baseline hypercalcemia is a hard contraindication. Confirms serum calcium remains within reference range.

Intact PTH (parathyroid hormone)

Primary efficacy biomarker: if Bonothyrk is working as theorized, PTH regulation should normalize toward reference range. Baseline establishes whether meaningful parathyroid dysfunction is present.

Serum phosphorus

PTH regulates phosphorus excretion inversely; tracking phosphorus provides a cross-check on calcium-phosphorus homeostasis and helps characterize the direction of any imbalance.

DEXA scan (bone mineral density)

Objective measurement of the primary claimed benefit. The only reliable way to verify whether BMD outcomes are occurring. Without imaging, bone effects cannot be self-assessed.

24-hour urine calcium

PTH stimulation increases urinary calcium excretion; stone formers are at elevated risk of new stone formation if urinary calcium rises. Establishes baseline and informs decision to proceed.

Bonothyrk Before and After

Days 1-7

No noticeable effects expected. The peptide complex begins interacting with parathyroid cells at the gene expression level. Some users report reduced frequency of muscle cramps.

Days 8-14

Subtle improvements in calcium-related symptoms may begin. Reduced muscle spasms and cramping have been reported anecdotally. Gene expression changes are believed to be underway.

Days 15-30

Full course effects should be building. Clinical observations suggest measurable improvements in bone mineral density markers by the end of a 30-day course, though individual results vary widely.

Months 1-4
post-course

Benefits are thought to persist for several months after completing a course due to sustained gene expression changes in parathyroid tissue. This is the rationale for the 4-6 month gap between courses.

6-12 months
repeat courses

Cumulative benefits with repeated courses are reported in Khavinson bioregulator literature. Bone density and calcium metabolism parameters may show progressive improvement across multiple treatment cycles.

What to Expect

Days 1 to 7, Course initiation. Nothing perceptible happens. Peptide fractions absorb through intestinal peptide transporters and theoretically reach parathyroid chief cells. No biochemical signal is expected. Some users get mild nausea or bloating in days 1 through 3 when taking capsules without food. Taking them with a meal fixes that.

Days 8 to 21, Accumulation phase. Epigenetic changes in parathyroid gene expression are theorized to build through DNA promoter binding. Labs would be the only way to detect it. A subset of users with calcium-related muscle cramps report reduced frequency starting around week 2. Most people notice nothing.

Days 22 to 30, Course completion. The 33-woman Khavinson observation showed measurable BMD marker improvements at day 30 versus controls. Muscle cramp reduction is the most consistently reported outcome. PTH regulation is theorized to be at least partially restored by course end.

Months 1 to 4 post-course, Carry-forward period. You stop dosing but effects don't stop. Khavinson's model predicts sustained gene expression changes in parathyroid tissue for 3 to 6 months. No crash effect reported. Calcium-related symptoms stay suppressed. Labs may continue showing calcium normalization.

Six months and beyond, Repeat courses. Experienced users run 2 to 3 annual courses. The broader Khavinson literature claims progressive improvement across treatment cycles. No independently verified data exists on cumulative Bonothyrk-specific outcomes. DEXA trends over 1 to 2 years are the only objective measure.

Detailed Timeline: Science vs Community

Days 1–7
Science

Peptide fractions absorb via intestinal peptide transporters and are theorized to reach parathyroid chief cells, interacting with gene promoter regions. No macroscopic effect or measurable biochemical signal expected at this stage.

Community

No subjective changes reported in this window. Mild GI adjustment (nausea, bloating) in a minority of users in days 1–3 when taken without food.

Days 8–21
Science

Epigenetic changes to parathyroid cell gene expression are theorized to accumulate via DNA promoter binding and RNA polymerase modulation. No measurable signal without serial intact PTH or calcium labs.

Community

A subset of users with calcium-related muscle cramps report reduced frequency beginning around week 2. The majority report no perceptible change in this window.

Days 22–30
Science

The sole cited clinical observation (Khavinson, 33 perimenopausal women) showed measurable BMD marker improvements at day 30 vs. controls. PTH regulation theorized to be at least partially restored.

Community

Reduction in muscle cramp frequency is the most consistently noted subjective outcome. Some users report improved musculoskeletal stability, though this is subjective and unverifiable without imaging.

Months 1–4 (post-course)
Science

Khavinson model predicts sustained gene expression changes in parathyroid tissue for 3–6 months post-course, allowing PTH regulation to remain improved without continued dosing.

Community

No crash effect reported upon stopping. Calcium-related symptoms remain suppressed during this period for most users. Labs may continue to show calcium normalization.

6+ months (repeat courses)
Science

Khavinson's broader bioregulator literature claims progressive BMD and calcium metabolism improvement across 2–3 annual courses. No independently verified data on cumulative Bonothyrk-specific outcomes.

Community

Experienced Khavinson bioregulator users run 2–3 annual courses and report sustained benefits with subsequent courses; primary self-assessment markers are absence of calcium-related symptoms and DEXA trends over 1–2 years.

Pharmacokinetics

Half-Life
3h
Bioavailability
Oral: estimated low to moderate for short-chain peptide fractions; exact value unknown
Tmax
~1-3 hours (estimated based on oral peptide absorption)
Data Confidence
low

Source: Estimated from general polypeptide fraction kinetics; no Bonothyrk-specific PK studies published (Khavinson & Anisimov, 2010)

Pharmacokinetics: Active Dose Over Time

t½ = ~2-6 hours (estimated, polypeptide complex)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Who Should Consider Bonothyrk

  • Perimenopausal and postmenopausal women at risk of osteoporosis
  • Older adults with age-related parathyroid gland decline
  • Individuals with suboptimal calcium metabolism markers
  • Patients recovering from parathyroid surgery or dysfunction
  • People with recurrent muscle cramps linked to calcium imbalance
  • Those seeking preventive support for bone mineral density maintenance

Related Peptides

What Changed for Bonothyrk

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20266 Citations

References

  1. [1]Peptide bioregulators: the new class of geroprotectors. Communication 1. Results of experimental studies (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Peptide Regulation of Gene Expression: A Systematic Review (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Peptide Regulation of Cell Differentiation (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Store in original blister packaging at room temperature, protected from moisture and light
After Reconstitution
N/A: oral capsule formulation, no reconstitution required
Temperature
15-25°C (59-77°F)

Frequently Asked Questions

No, this is a hard contraindication. If the parathyroid gland has been removed, there is no tissue for Bonothyrk to act on. Post-surgical hypoparathyroidism requires calcitriol and calcium supplementation managed by an endocrinologist.

The Khavinson model claims these peptides normalize gene expression rather than replace endocrine output, theoretically without receptor downregulation. However, no long-term dependency study exists in English-indexed literature. Monitoring PTH and serum calcium before and after courses is the practical safeguard.

Product literature describes bidirectional normalization, but primary hyperparathyroidism caused by adenoma requires surgery or cinacalcet. Bonothyrk is not a substitute. For functional or age-related parathyroid decline, use is more consistent with the theoretical mechanism. Any use for PTH dysregulation should involve an endocrinologist given the calcium homeostasis stakes.

The lingual form bypasses first-pass metabolism and gut acid degradation, theoretically improving bioavailability. However, the sublingual dosing guidance (7.5–14 mg total/day) is actually a lower total daily dose than the standard capsule protocol (20–40 mg/day). No head-to-head bioavailability study exists.

The 30-day clinical study showed measurable BMD changes by course end, with carry-forward effects continuing 3–6 months post-course. Recommended monitoring: serum calcium (total and ionized), intact PTH, serum phosphorus, and DEXA scan at baseline and 6 months. Check serum calcium before starting to rule out pre-existing hypercalcemia.